Entering text into the input field will update the search result below

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q2 2022 Results - Earnings Call Transcript

Aug. 02, 2022 7:58 PM ETGilead Sciences, Inc. (GILD)2 Comments
SA Transcripts profile picture
SA Transcripts

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET

Company Participants

Jacquie Ross - VP, IR

Daniel O'Day - Chairman & CEO

Johanna Mercier - Chief Commercial Officer

Merdad Parsey - Chief Medical Officer

Andrew Dickinson - EVP & CFO

Christi Shaw - CEO, Kite

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Geoffrey Meacham - Bank of America

Tyler Van Buren - Cowen and Company

Olivia Brayer - Cantor Fitzgerald

Umer Raffat - Evercore ISI

Matthew Harrison - Morgan Stanley

David Risinger - SVB Securities

Salveen Richter - Goldman Sachs

Michael Yee - Jefferies

Steven Seedhouse - Raymond James

Carter Gould - Barclays

Mohit Bansal - Wells Fargo


Good day and thank you for standing by. Welcome to Gilead Sciences Second Quarter 2022 Earnings Conference Call. All lines have been placed on mute to prevent background noises. After today’s remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's call is being recorded.

I would now like to hand the conference over to Jacquie Ross, Vice President of Investor Relations. Please go ahead.

Jacquie Ross

Thank you, operator, and good afternoon, everyone. Just after market close today, we issued a press release with earnings results for the second quarter of 2022. The press release, slides and supplemental data are available on the Investors section of our website at gilead.com.

The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Merdad Parsey; and our Chief Financial Officer, Andrew Dickinson. After that, we'll open up the call to Q&A where the team will be joined by Christi Shaw, the Chief Executive Officer of Kite.

Before we get started, let me remind you that we will

Recommended For You

Comments (2)

Given Trodelvy's grade 1 recommendation in mTNBC treatment and lencapavir q 6mths for HIV you'd expect to see that translated into the price point for GILD and yet it's barely moved.
This is about as upbeat as I've heard them since curing Hep-C.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.